News related to
Chinese

Goldman Sachs Group Inc. has cautioned that Brent crude oil prices could plummet below $40 per barrel under extreme scenarios, as escalating trade tensions between the United States and China exacerbate fears of a global economic downturn. This warning follows the bank’s recent downward revision of its 2025 Brent crude forecast to $77 per barrel, a $5 reduction from earlier estimates, citing unexpected increases in oil inventories and sluggish demand growth from China.

The ongoing trade dispute has led to significant market volatility, with President Donald Trump’s administration imposing tariffs of up to 60% on Chinese goods and 25% on steel imports. These aggressive measures have rattled global markets, leading to a bear market for the S&P 500 and substantial losses across major indices, including the FTSE 100 and DAX.

In response to these developments, OPEC+, the alliance of the Organization of the Petroleum Exporting Countries and its partners, announced an unexpected production increase of 411,000 barrels per day starting in May. This move aims to discipline non-OPEC supply but has contributed to a surplus, further depressing oil prices.

Analysts at Goldman Sachs have outlined several scenarios that could lead to a sharp decline in oil prices. For instance, if Chinese oil demand remains flat, Brent crude could drop to $60 per barrel. Additionally, the imposition of a comprehensive 10% tariff on imported goods by the U.S. could drive prices down to $63 per barrel. A full reversal of OPEC’s additional production cuts of 2.2 million barrels per day could further push prices to $61 per barrel.

The repercussions of these developments are multifaceted. While consumers may benefit from lower fuel prices, energy companies, particularly those involved in U.S. shale production, face significant financial strain. Major firms such as Chevron, Occidental Petroleum, and Diamondback Energy have already experienced notable stock declines.

The broader economic implications are equally concerning. The combination of escalating trade tariffs and increased oil production has heightened fears of a global recession. Financial institutions, including JPMorgan, have raised their recession forecasts, reflecting the growing economic uncertainties.

Chinese social media platforms are abuzz with users expressing strong opposition to suggestions that Beijing should acquiesce to U.S. trade demands following President Donald Trump’s recent tariff escalations. The online discourse reflects a nationalistic sentiment, with many netizens urging the Chinese government to stand firm against what they perceive as economic intimidation.

President Trump announced a 10% baseline tariff on all imports, with significantly higher duties targeting specific countries, including a 54% tariff on Chinese goods. This move has intensified trade tensions between the world’s two largest economies. In retaliation, China imposed a 34% tariff on various American products, signaling its resolve to counter U.S. measures.

The Chinese Foreign Ministry’s spokesperson, Guo Jiakun, highlighted the global market’s adverse reaction to the U.S. tariffs, stating, “The market has spoken.” This remark underscores Beijing’s position that the U.S. actions are disruptive to international trade stability.

State-run media outlets have also weighed in, criticizing the U.S. administration’s approach. The Global Times labeled the tariff threats as “ridiculous” and indicative of “deep arrogance,” while China Daily warned that such actions could lead to a “mutually destructive tariff war.”

On platforms like Weibo and WeChat, Chinese citizens are vociferously rejecting any notion of capitulation. Users are calling for unity and resilience, emphasizing the importance of safeguarding national interests and economic sovereignty. This collective online sentiment reflects a broader public consensus supporting the government’s stance in the escalating trade dispute.

Indian metal companies are significantly expanding their operations, driven by robust domestic demand, even as they navigate complex global trade dynamics. Industry leaders such as Vedanta and JSW Steel are at the forefront of this growth, unveiling ambitious plans to scale up production capacities across various segments.

Vedanta, a prominent conglomerate, has announced a $20 billion expansion strategy encompassing sectors like zinc, aluminium, copper, iron, steel, oil, gas, and power. This initiative includes seeking global partnerships to bolster its ventures. The company is also in the process of restructuring into four distinct entities: Vedanta Aluminium, Oil and Gas, Power, and Iron and Steel. Notable investments involve allocating $2 billion to $2.5 billion for enhancing Hindustan Zinc’s production and $5 billion aimed at increasing oil output through Cairn India. Additionally, Vedanta plans to double its power portfolio and explore opportunities in nuclear energy, targeting 5 GW of nuclear power for internal consumption within India.

JSW Steel, another major player, is pursuing an aggressive expansion trajectory. The company aims to elevate its production capacity from the current 27.5 million tonnes per annum to 38.5 mtpa by the fiscal year 2024-25. This growth strategy includes commissioning iron ore and coal mines in Karnataka, Odisha, and Goa, which is expected to reduce operational costs. JSW Steel is also investing in renewable energy projects to further decrease production expenses. The company has set a target to reach a 50 mtpa capacity before 2030, reflecting confidence in sustained domestic demand growth.

Tata Steel is also contributing to the industry’s expansion by adding 5 million tonnes to its existing 21 mtpa capacity. Similarly, Jindal Steel and Power plans to increase its capacity by 6 million tonnes, building upon its current 9.6 mtpa. Collectively, these initiatives represent a substantial investment aimed at capitalizing on India’s burgeoning steel consumption, which is projected to grow between 8% to 10% in the fiscal year 2024-25.

The Indian government’s policy measures are playing a crucial role in supporting domestic manufacturers. The “Domestically Manufactured Iron and Steel Products Policy 2025,” effective from April 1, mandates that all government ministries and agencies prioritize locally produced steel products. This policy aims to protect the domestic steel industry from the influx of cheaper imports, particularly from countries like China, South Korea, and Japan. It also restricts the use of foreign certifications or stringent technical specifications that could disadvantage local suppliers and bars foreign entities from participating in Indian tenders if their home countries impose procurement restrictions on Indian mills.

Despite these protective measures, Indian steelmakers face challenges from international trade policies. The United States has imposed a flat 26% reciprocal tariff on all Indian exports, citing high Indian tariffs on U.S. goods. This move is expected to impact key Indian export sectors, including electronics, gems and jewellery, and certain aluminium and auto parts. However, pharmaceuticals and energy products are exempt from these tariffs. In response, India is engaging in negotiations with the U.S. for a new trade deal and has expressed willingness to reduce tariffs on $23 billion worth of U.S. imports. Additionally, India is exploring opportunities to expand exports in sectors like textiles, apparel, footwear, and steel, particularly as higher tariffs are levied on Chinese goods.

The global shipping industry is experiencing significant upheaval following the implementation of extensive tariffs by U.S. President Donald Trump. These measures, including a 25% tariff on imports from Canada and Mexico and a 10% levy on Chinese goods, have disrupted international trade flows and introduced widespread economic uncertainty.

In anticipation of these tariffs, container vessel traffic to American ports surged by 12% last month, reaching a record 281 port calls in the week ending March 13, as reported by Ami Daniel of AI data provider Windward. This rush to ship goods ahead of the tariffs has complicated annual freight contract negotiations, set to begin on May 1, according to Norwegian analytics firm Xeneta. Asian shipping companies have responded by raising prices for routes to the U.S. to offset the expected tariffs on Chinese-built ships, as noted by Singapore-based Linerlytica.

The automotive sector has been notably affected. Jaguar Land Rover announced a temporary halt to exports of its British-made vehicles to the U.S. in response to the 25% import tariff. The company, which exports nearly a quarter of its 400,000 annual vehicle sales to the U.S., is assessing the financial impact and exploring options such as price increases for American consumers and boosting sales in other markets. Other UK-based automakers, including BMW, Rolls-Royce, and Ineos Automotive, are also evaluating their responses, with Ineos already raising U.S. prices.

The financial markets have reacted sharply to the tariff announcements. The Dow Jones Industrial Average and S&P 500 experienced significant declines over the past week, falling 7.9% and 9.1%, respectively, with the Dow dropping over 2,200 points on Friday alone. China responded with retaliatory 34% tariffs, escalating fears of a deepening trade war. Experts, including Moody’s chief economist Mark Zandi, warned that the tariffs could hinder productivity, damage the U.S.’ investment image, and prompt global allies to distance themselves from U.S. trade.

In the United Kingdom, Prime Minister Keir Starmer is considering a significant reset of the country’s economic policies in response to the U.S. tariffs. The FTSE 100 has plummeted over 7% in its worst week since the COVID-19 panic in March 2020. Amid fears of a prolonged recession, Starmer and Chancellor Rachel Reeves are reportedly contemplating raising taxes or altering fiscal rules to increase borrowing and stimulate growth, despite previous pledges to the contrary. British businesses, such as JLR, are already feeling the pressure, with the automotive sector particularly vulnerable due to its reliance on exports to the U.S.

The tariffs have also intensified discussions around supply chain deglobalization. Companies are reassessing their sourcing strategies, with potential shifts toward domestic production and alternative countries like Vietnam and India. This trend is driven by the need to mitigate the impact of tariffs and reduce reliance on any single country for manufacturing. However, such shifts are complex and require significant investment and time to implement.

The shipping industry is facing additional challenges due to the removal of the de minimis exemption for shipments under $800 from Canada, Mexico, and China. This change means that goods arriving by air will be subject to the new and existing tariffs, incur significant filing requirements and costs, and take longer to clear customs. This development could sharply reduce air cargo volumes from China to the U.S., leading to downward pressure on transpacific air cargo rates and potentially affecting the broader air cargo market.

Industry leaders are expressing concern over the escalating trade tensions. Billionaire Elon Musk expressed hopes for a future zero-tariff trade zone between North America and Europe. Meanwhile, leaders from the UK and France emphasized the importance of global cooperation and warned against the detrimental effects of trade wars. Italy’s economy minister cautioned against retaliatory actions and urged a rational response to safeguard Europe’s economic interests.

Oil markets witnessed a significant downturn as Brent crude, the global benchmark, tumbled over 13% in two days, settling just above $66 per barrel. This sharp decline follows the dual impact of OPEC+ unexpectedly increasing production and the imposition of new tariffs by President Donald Trump.

On April 4, 2025, Saudi Arabia led an initiative within OPEC+ to substantially boost oil output by 411,000 barrels per day starting in May. This move aims to penalize member countries like Kazakhstan and Iraq for consistently exceeding production quotas. The decision contributed to an 8% drop in oil prices, with Brent crude falling below $65 per barrel for the first time since 2021.

Concurrently, President Trump intensified trade tensions by imposing tariffs on imports from Canada, China, and Mexico. China responded with a retaliatory 34% tariff on U.S. imports, escalating fears of a global economic slowdown and further pressuring oil prices.

Goldman Sachs revised its 2025 oil price forecasts downward, cutting Brent crude to $69 and West Texas Intermediate to $66 per barrel. JPMorgan raised its global recession probability to 60%, up from 40%, reflecting growing concerns over economic stability.

The surge in supply and escalating trade disputes have led to significant losses in energy stocks. Major oil companies, including Chevron, APA, Occidental Petroleum, and Diamondback Energy, experienced notable declines. The Energy Select Sector SPDR ETF fell nearly 7% on the day and almost 13% for the week.

Analysts suggest that until production is significantly reduced, oil prices may continue to fall. The geopolitical backdrop includes U.S. relations with Saudi Arabia, key to both energy policy and diplomatic efforts related to Russia, Iran, and broader Middle East tensions.

In contrast, natural gas stocks have shown resilience, supported by rising LNG exports and less exposure to OPEC’s dynamics. Companies like EQT, Expand Energy , and Coterra Energy are highlighted as attractive investments due to geographic advantages and favorable valuations.

The current downward trend in oil prices is primarily driven by OPEC+’s decision to increase output and the introduction of U.S. tariffs. Analysts expect the tariffs to curb economic activity and demand for energy, weighing on oil prices. The bank also said higher-than-expected crude supply and a demand squeeze from softer U.S. economic activity and tariff escalation posed downside risks to oil price forecasts.

The Organization of the Petroleum Exporting Countries and its allies, known as OPEC+, decided on Monday to increase output for the first time since 2022, further pressuring crude prices. The group will make a small increase of 138,000 barrels per day from April, the first step in planned monthly increases to unwind its nearly 6 million bpd of cuts, equal to almost 6% of global demand.

The larger-than-expected decline in crude stocks supported the downward trend in oil prices, pointing to weakening demand in the U.S. The U.S. Energy Information Administration is expected to announce the official inventory data during the day.

The risks to oil prices remain tilted to the downside with new supply from OPEC+ and non-OPEC producers expected to push the market well into an oversupply. Brent prices on Wednesday fell to their lowest since December 2021 after U.S. crude inventories rose and in the wake of the decision by OPEC+ to increase their output quotas.

Oil prices had already been trading lower in the last few weeks, partly because of expectations that U.S. president Donald Trump could swiftly end Russia’s war in Ukraine. This, in turn, is likely to increase Russian oil output thanks to sanctions relief.

The benchmark previously dropped to $66.77 a barrel, the lowest since November. “The current downward trend in oil prices is primarily driven by OPEC+’s decision to increase output and the introduction of U.S. tariffs,” said Darren Lim, commodities strategist at Phillip Nova. He said another factor was President Donald Trump’s decision to pause all U.S. military aid to Ukraine after his Oval Office clash with President Volodymyr Zelenskiy last week.

Those politics are likely connected with the wheeling and dealing of Donald Trump, referring to the U.S. president’s calls for lower oil prices. U.S. tariffs of 25% on imports from Canada and Mexico took effect at 12:01 a.m. EST on Tuesday, with 10% tariffs on Canadian energy, while tariffs on imports of Chinese goods were increased to 20% from 10%. Analysts expect the tariffs to curb economic activity and demand for energy, weighing on oil prices.

The bank also said higher-than-expected crude supply and a demand squeeze from softer U.S. economic activity and tariff escalation posed downside risks to oil price forecasts. Chinese demand is also down, with a period of refinery maintenance looming, said Josh Callaghan, head of crude derivatives at Arrow Energy Markets.

Oil prices declined for a third day on Wednesday, as investors worried about OPEC+ plans to proceed with output increases in April, and U.S. President Donald Trump’s tariffs on Canada, China, and Mexico escalated trade tensions. Brent futures fell $1.02, or 1.44%, to $70.02 a barrel by 1149 GMT. U.S. West Texas Intermediate crude declined $1.33, or 1.95%, to $66.93 a barrel.

The escalating trade conflict between the United States and China has introduced significant shifts in global trade dynamics, presenting both opportunities and challenges for Indian exporters. The U.S. administration’s imposition of substantial tariffs on Chinese imports has prompted China to retaliate with its own set of tariffs, affecting a broad spectrum of goods. This tit-for-tat exchange has disrupted established supply chains, leading American importers to seek alternative sources for various products.

Indian exporters are poised to benefit from this realignment, particularly in sectors where India has a competitive edge. Industries such as agriculture, engineering, textiles, chemicals, and leather are witnessing increased interest from U.S. buyers aiming to diversify their supply chains away from China. Ajay Sahai, Director General of the Federation of Indian Export Organisations , noted that U.S. buyers are approaching Indian companies with manufacturing operations in China, requesting them to supply from their Indian facilities due to the prevailing uncertainties.

The agricultural sector stands to gain notably, with products like soybeans and seafood emerging as viable alternatives to Chinese exports. Similarly, the engineering and machine tools industries are experiencing heightened demand, as American companies look to mitigate the impact of increased tariffs on Chinese machinery. The textiles and garments sector is also seeing a surge in orders, capitalizing on India’s established reputation in these markets.

However, this shift is not without its challenges. The increased tariffs on Chinese goods have led to concerns about the potential for these products to be redirected to other markets, including India, at lower prices. This scenario raises the specter of dumping, which could adversely affect domestic manufacturers. Crisil, a global analytics company, has highlighted that as the U.S. imposes higher tariffs on Chinese imports, there is a heightened possibility of these surplus goods being diverted to countries like India, potentially disrupting local industries.

In response to these developments, the Indian government is actively engaging with exporters to assess the evolving landscape and identify strategies to capitalize on emerging opportunities. Efforts are underway to enhance manufacturing capabilities, streamline regulatory processes, and improve infrastructure to better position Indian products in the global market. The government’s proactive stance aims to not only seize the openings created by the U.S.-China trade tensions but also to safeguard domestic industries from potential negative spillovers.

Beijing has announced the imposition of a 34% tariff on all imports from the United States, effective April 10, 2025, in direct response to the sweeping tariffs introduced by U.S. President Donald Trump. The Chinese Ministry of Finance stated that this measure aims to counteract what it perceives as unjust and protectionist policies from Washington.

This development follows President Trump’s declaration of “Liberation Day” on April 2, during which he unveiled a universal 10% tariff on all foreign imports, with higher rates for specific countries. China was notably targeted with an additional 34% tariff, bringing the total levy on Chinese goods to 54%. The U.S. administration justified these tariffs as necessary to rectify longstanding trade imbalances and to protect domestic industries.

In a statement, China’s Ministry of Finance condemned the U.S. actions, urging Washington to immediately withdraw the imposed tariffs to prevent further escalation. The ministry emphasized that China’s countermeasures are a legitimate response to safeguard its national interests and the multilateral trading system.

The U.S. tariffs have been met with criticism from various quarters. Economists have expressed concerns over the methodology used to calculate these tariffs, arguing that the approach is overly simplistic and could lead to unintended economic consequences. They warn that such measures might not effectively address trade deficits and could harm consumers through increased prices.

The business community is also bracing for the impact of these tariffs. In New York City, retailers are encouraging consumers to make purchases before the new tariffs lead to price increases. Products such as electronics, appliances, and automobiles are expected to see significant price hikes, prompting a surge in sales ahead of the tariff implementation.

China’s retaliatory tariffs are anticipated to affect a wide range of U.S. exports, including agricultural products, automobiles, and technology goods. This move is expected to have significant implications for American farmers and manufacturers who rely heavily on the Chinese market. Analysts predict that the escalating trade war could disrupt global supply chains and dampen economic growth in both countries.

Pfizer has unveiled its new research and development centre in Beijing, marking a significant step in the company’s strategic expansion in China. The facility, located within the BioPark in the Beijing Economic-Technological Development Area , represents the pharmaceutical giant’s ongoing commitment to increasing its presence in the Chinese market. This development comes at a time when global healthcare companies are intensifying their focus on innovation in key Asian markets.

The opening of the R&D centre is expected to bolster Pfizer’s research capabilities, particularly in the development of cutting-edge treatments in areas such as oncology, vaccines, and rare diseases. The new centre will serve as a hub for collaborative efforts between Pfizer and local Chinese researchers, healthcare providers, and academic institutions. This collaboration is viewed as a strategic move to accelerate the discovery and delivery of new therapies tailored to both global and regional healthcare needs.

Pfizer’s decision to open a new R&D centre in Beijing underscores the company’s long-term investment in China’s growing pharmaceutical industry. It is also a response to the Chinese government’s push to modernise its healthcare infrastructure and increase the availability of advanced medical treatments to its population. China’s robust investment in healthcare innovation and its vast population present a significant opportunity for Pfizer to lead in areas of unmet medical need.

The Beijing facility will focus on the integration of new technologies, such as artificial intelligence and data analytics, into drug discovery and clinical development processes. These technologies are expected to streamline Pfizer’s ability to identify promising drug candidates more efficiently, reducing development timelines and improving outcomes for patients worldwide. The centre will also support the company’s efforts to create vaccines and treatments specifically designed for the Chinese market.

Local Chinese health experts have welcomed the initiative, highlighting the positive impact it is likely to have on the region’s pharmaceutical ecosystem. Collaborations between international pharmaceutical companies like Pfizer and domestic research institutions are seen as vital to addressing health challenges in China, including the increasing prevalence of chronic diseases and an ageing population. The government’s support of such ventures is also expected to foster a more innovative and competitive environment in the Chinese pharmaceutical sector.

Pfizer’s expansion into Beijing is not the company’s first move in the region. Over the past decade, the pharmaceutical leader has steadily increased its investments in China, with a particular focus on expanding its clinical trials and vaccine development operations. This new R&D centre further cements the company’s position as a key player in the Chinese healthcare landscape.

One of the critical drivers behind Pfizer’s decision to build the facility in Beijing is the strategic importance of the region’s role in global drug development. The Chinese market, one of the largest in the world, has seen rapid growth in demand for healthcare products, particularly in biotechnology, oncology treatments, and vaccines. With an increasingly affluent population, China’s demand for high-quality medical products has surged, presenting a strong business case for Pfizer to deepen its engagement with the market.

The opening of this facility aligns with Pfizer’s broader global strategy to strengthen its innovation pipeline and maintain its competitive edge in the pharmaceutical industry. The company has consistently emphasised the importance of R&D as a cornerstone of its business model, and this move further emphasises its commitment to discovering new therapies for complex diseases. The Beijing centre is expected to collaborate with Pfizer’s other global R&D hubs, contributing to a more interconnected and agile research network.

Pfizer’s global operations have also faced some challenges in recent years, particularly with the economic uncertainties brought on by the pandemic. However, the company’s strategy of investing in emerging markets like China reflects its resilience and focus on future growth. By establishing a physical presence in one of the world’s most dynamic pharmaceutical markets, Pfizer is positioning itself to tap into both immediate and long-term opportunities in China and beyond.

The Chinese government has been supportive of multinational companies that invest in high-tech industries such as pharmaceuticals and biotechnology. This policy environment has made it increasingly attractive for foreign companies to set up R&D centres and collaborate with Chinese firms. In return, China benefits from the influx of advanced medical technologies and expertise, further propelling its ambitions to become a leader in global healthcare innovation.

Pfizer’s Beijing R&D centre is part of a broader trend of Western pharmaceutical companies making significant investments in China. These companies are increasingly collaborating with local research institutions to foster innovation, improve patient care, and support the country’s healthcare development goals. Such investments are also aligned with China’s ongoing reforms aimed at modernising its healthcare system, ensuring broader access to innovative treatments, and addressing the nation’s rising health challenges.

The opening of the R&D centre also highlights Pfizer’s commitment to ensuring that new therapies developed in Beijing will be available not only to the Chinese market but also to the global community. With the centre poised to focus on therapies for diseases with high unmet needs, including cancer and infectious diseases, the potential for cross-border medical collaboration is immense. Pfizer’s ability to leverage the centre’s local expertise and technological advancements will play a crucial role in meeting both Chinese and global healthcare demands.

Foxconn, Apple’s primary manufacturing partner, plans to produce 25 to 30 million iPhones in India this year, more than doubling its output from the previous year. This move underscores Apple’s strategy to strengthen its manufacturing footprint in India and diversify its supply chain amid global uncertainties.

The Taiwanese contract manufacturer has been conducting trial runs at its facility in Bengaluru, Karnataka, aiming to meet Apple’s stringent quality standards and production targets. This initiative aligns with Apple’s broader objective to reduce reliance on Chinese manufacturing and mitigate risks associated with geopolitical tensions and supply chain disruptions.

Foxconn’s expansion in India is part of a larger trend of global tech companies seeking alternative manufacturing hubs. India’s Production-Linked Incentive scheme has been instrumental in attracting such investments by offering financial incentives to boost domestic manufacturing. In the fiscal year ending March 2023, Foxconn produced approximately ₹300 billion worth of iPhones, surpassing the PLI scheme’s cap of ₹200 billion, indicating the program’s success in scaling up production.

In addition to iPhone assembly, Apple is broadening its product manufacturing in India. A unit of Foxconn is set to commence the assembly of AirPods at a new factory near Hyderabad, Telangana, by early 2025, following successful trial productions. This diversification reflects Apple’s commitment to expanding its product assembly capabilities within the country.

However, the expansion has encountered challenges. Reports suggest that China is imposing restrictions on the movement of employees and specialized equipment essential for high-tech manufacturing to India and Southeast Asia. These measures appear aimed at limiting technology transfers and mitigating potential job losses, posing obstacles to Apple’s efforts to diversify its production bases.

Despite these hurdles, Apple’s manufacturing partners in India are making significant strides. Tata Electronics has acquired a 60% stake in Pegatron Technology India, which manages an iPhone plant near Chennai. This acquisition positions Tata as a formidable competitor to established players like Foxconn in the Indian iPhone manufacturing landscape.

The Indian government’s support has been pivotal in this expansion. Foxconn is establishing a mobile phone manufacturing plant in the Devanahalli Industrial Area, Bengaluru, with an investment of ₹21,911 crore. The company will receive incentives amounting to ₹6,970 crore under the Electronics System Design and Manufacturing policy, as announced by Karnataka’s Chief Minister.